EMA Authorised: Zyclara (imiquimod) — Viatris Healthcare Limited

View source ↗

Summary

The EMA authorised Zyclara (imiquimod) for actinic keratosis, with Viatris Healthcare Limited listed as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• ZYCLARA (Imiquimod)

Snippet

Status: Authorised. Therapeutic area: Keratosis;Keratosis, Actinic. MAH: Viatris Healthcare Limited. Decision date: 21/07/2025